ML385: A Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a potent and selective small molecule inhibitor of the transcription factor NRF2, with an IC50 of 1.9 μM, used extensively in cancer biology and oxidative stress research (APExBIO product information). It effectively downregulates NRF2-dependent gene expression in a dose- and time-dependent manner, as demonstrated in A549 NSCLC cell lines. In vivo, ML385 impairs tumor growth and metastasis in non-small cell lung cancer (NSCLC) models, especially when combined with chemotherapeutics (Zhou et al., 2024). ML385 is also utilized to probe mechanisms of ferroptosis and inflammation, with evidence supporting its role in modulating oxidative stress. The compound is supplied at ≥98% purity, with recommended storage at -20°C, and is not intended for clinical use (APExBIO).

Biological Rationale

NRF2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that orchestrates cellular antioxidant defense, detoxification, and multidrug transporter expression. Its hyperactivation is a common feature in various cancers, particularly NSCLC, conferring survival advantages and therapeutic resistance to malignant cells (Zhou et al., 2024). Modulation of NRF2 is increasingly recognized as a strategy to overcome drug resistance and sensitize tumors to chemotherapy. Additionally, NRF2 influences genes involved in NADPH production and redox balance, placing it at the nexus of oxidative stress and ferroptosis regulation. In liver disease models, NRF2 inhibition has illuminated the pathway’s role in cell death and inflammation, expanding the utility of selective inhibitors like ML385 beyond oncology (see related study).

Mechanism of Action of ML385

ML385 specifically binds to the Neh1 DNA-binding domain of NRF2, inhibiting its transcriptional activity. This results in suppression of NRF2-driven gene expression, including those encoding antioxidant proteins and detoxification enzymes. In cancer models, this mechanism leads to enhanced sensitivity to chemotherapeutic agents and reduced tumor cell viability. In the context of oxidative stress, ML385-mediated NRF2 inhibition reduces the expression of genes that neutralize reactive oxygen species, thereby promoting ferroptosis under specific conditions (Zhou et al., 2024).

Evidence & Benchmarks

• ML385 inhibits NRF2 with an IC50 of 1.9 μM in cell-free assays and effectively downregulates NRF2 target genes in A549 NSCLC cells (APExBIO product information).
• In NSCLC mouse models, ML385 monotherapy reduced tumor growth and metastasis, with further suppression observed when paired with carboplatin (Zhou et al., 2024).
• ML385 administration at 100 mg/kg/day (i.p.) in rodent models demonstrated robust NRF2 pathway inhibition and modulation of oxidative stress markers over 6 weeks (Zhou et al., 2024).
• In alcoholic liver injury models, ML385 reversed the protective effect of Poria cocos polysaccharides, confirming its role as a functional NRF2 inhibitor in vivo (Zhou et al., 2024).
• ML385 is insoluble in ethanol and water but dissolves at ≥13.33 mg/mL in DMSO, facilitating its use in cell culture and animal studies (APExBIO product information).

This article extends the practical protocol focus of ML385: NRF2 Inhibitor Workflows for Cancer and Ferroptosis Research by integrating recent disease model evidence and updated combination strategies. It also clarifies the mechanistic underpinnings detailed in Strategic NRF2 Inhibition: ML385 as a Transformative Tool... by providing new in vivo validation benchmarks, and updates the translational context reviewed in Strategic NRF2 Inhibition in Translational Research: Mech... with direct reference to clinical resistance scenarios.

Applications, Limits & Misconceptions

ML385 is primarily deployed in research investigating NRF2 pathway inhibition in cancer, oxidative stress, and ferroptosis. Its ability to modulate NRF2 activity enables studies on therapeutic resistance mechanisms, combinatorial drug efficacy, and the cellular response to oxidative insults. ML385 has also been instrumental in elucidating the interaction between NRF2 and inflammatory signaling in both hepatic and pulmonary models. However, its application is restricted to preclinical research settings. ML385 is not suitable for diagnostic or medical use in humans (APExBIO).

Common Pitfalls or Misconceptions

• Clinical Use: ML385 is not approved for therapeutic or diagnostic applications; use is limited to research only (APExBIO).
• Solubility: The compound is insoluble in water and ethanol; improper dissolution can lead to variable dosing (APExBIO).
• Long-Term Storage: Solutions of ML385 are not stable for long-term storage; freshly prepare before use.
• Off-target Effects: While highly selective for NRF2, off-target effects at supra-physiological concentrations cannot be excluded (Zhou et al., 2024).
• Species Differences: Efficacy and toxicity profiles may differ between cell lines, rodents, and other models.

Workflow Integration & Parameters

• Stock Solution Preparation: Dissolve ML385 in DMSO at concentrations up to 13.33 mg/mL, vortex thoroughly, and filter-sterilize if required (APExBIO product information).
• Cell Culture Dosing: Typical working concentrations range from 1–10 μM, with 24–72 hour incubation in established NRF2-dependent cell lines (protocol guidance).
• Animal Studies: Administer 100 mg/kg/day intraperitoneally for 4–6 weeks in murine models; adjust dosing based on body weight and experimental design (Zhou et al., 2024).
• Combination Therapy: For synergy studies, co-administer with standard chemotherapeutics (e.g., carboplatin) and monitor tumor response, oxidative stress, and survival endpoints (see workflow).
• Storage: Store ML385 solid or frozen solution at -20°C. Do not store working solutions long-term (APExBIO).

Conclusion & Outlook

ML385, as a selective NRF2 transcription factor inhibitor, provides a reliable research tool for dissecting the NRF2 signaling pathway in cancer, oxidative stress, and ferroptosis contexts. Its efficacy in cell and animal models, particularly in overcoming cancer therapeutic resistance and modulating ferroptosis, is well-supported by recent studies (Zhou et al., 2024). The reagent’s robust performance and ease of integration into established workflows have made it a mainstay for translational and mechanistic studies. However, its use remains restricted to preclinical research. Future work may clarify its translational limits and broader applications within regulated settings, but current evidence positions ML385 as a benchmark for NRF2 pathway inhibition in experimental biology.